MERZ-AESTHETICS
31.3.2022 09:02:11 CEST | Business Wire | Press release
Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics at the 20th Aesthetic & Anti-Aging Medicine World Congress (AMWC), with the presentation of data from its medical aesthetics portfolio and a clear focus on addressing the aesthetic needs of a diverse society. AMWC 2022, held from Thursday, 31 March to Saturday, 02 April 2022, will take place in a hybrid format, enabling participants to attend the conference in person in Monaco and/or virtually. Merz Aesthetics is an elite sponsor of the global industry congress.
“As part of our continued commitment to the aesthetic medicine industry, we are looking forward to reunite with partners and experts, share insights and foster scientific exchange in the aesthetics field at this year’s AMWC congress,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics. “We are focused to advance science in aesthetics, fuel confidence and empower unique attitudes.”
Merz Aesthetics continues to embrace the diversified and unique needs of aesthetic patients and practitioners, recognizing the personal journey for each patient and partnering with experts to meet those needs – by fueling confidence and empowering unique attitudes.
Merz Aesthetics is organizing an expert program led by esteemed medical aesthetic experts and presenting new data throughout the course of the meeting.
Expert Keynote Sessions
Merz Aesthetics is organizing expert-led keynote sessions to be held on Thursday, 31 March – Friday, 01 April (via registration only).
- “Skin Glow and Skin Quality – optimizing your skin boosting treatment” – Dr. Sonja Sattler, Thursday, 31 March, 10:00-12:00h CEST.
- “Collagen Expert Class – insights into collagen stimulation, skin quality and patient safety” – Dr. Jani van Loghem, Thursday, 31 March, 13:00-15:00h CEST.
- “Optimizing the Patient Journey in the Digital Age” – Adam Haroun, Thursday, 31 March, 15:30-17:00h CEST.
- “Aesthetic Toxin Expert Talk – purity and precision for long-term patient satisfaction” – Dr. Carla Pecora, Friday 01 April, 10:00-12:00h CEST.
- “Skin Lifting – the expert approach to customized treatments” – Dr. Tatjana Pavicic, Friday 01 April, 13:00-15:00h CEST.
- “All About Lips – expert techniques to address the unique needs of patients” – Dr. Kate Goldie, Friday 01 April, 15:30 – 17:30h CEST
Oral Presentations
Dr. Carla Pecora: ‘Clinical experience with intradermal microdroplet injection of diluted Incobotulinum toxin A for facial flushing and pore size improvement’ (Neuromodulators); Saturday, 02 April, 9:00h CEST, Nijinski
Dr. Carla Pecora: ‘A combination approach using IncobotulinumtoxinA and CPM-HA injections for the periorbital complex improvement.’ (Periorbital Zone and “Foxy Eyes” Trend – Lifting & Rejuvenating); Saturday, 02 April, 11:15h CEST, Salle des Princes & AMWC Stream 1
E-Poster Presentations
Virtual posters will be available for viewing for the duration of the congress and displayed on the virtual E-poster platform with detailed abstracts.
Botulinum Toxin
- Study Design of LONG RUN: A LONGitudinal evaluation and Real-world evidence of Uniquely purified incobotulinumtoxinA in treatment naïve participants. Andy Curry, Merz Aesthetics - USA, Terrence Keaney, MD – USA, Niamh Corduff, MD – Australia, Simon Ravichandran, MD – UK, Ada Trindade, MD – Brasil.
- Chemobioresurfacing: Does intradermal injection of botulinumtoxinA plus hyaluronic acid improve skin quality? Diane Duncan, MD – USA.
- IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines: Final Study Results. Martina Kerscher, MD PhD – Germany, Sabrina Fabi, Md – USA, Tanja Fischer, MD PhD – Germany, Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, PhD – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.
Belotero® and Radiesse®
- The local tissue lifting capacity of dermal filler is greater with increasing hyaluronic acid concentration using an ex vivo human skin model. Kay Marquardt, Christian Hartmann, Christina Wollenburg, Tristan Gesing, Thomas Hengl – all Merz Aesthetics, Germany.
- Distance between calcium hydroxylapatite microspheres is essential for fibroblast invasion and resulting neocollagenesis. Bartosch Nowag, Nils Warfving, Thomas Hengl – all Merz Aesthetics, Germany.
- Comparative Histomorphological Evaluation of the Injectable Cohesive Polydensified Matrix Hyaluronic Acid and Calcium Hydroxylapatite Combination. Yana Yutskovskaya, MD – Russia, Evgenia Kogan, MD PhD – Russia, Alla Y Koroleva, MD – Russia.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves—however they define it. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with a commercial presence in 36 countries worldwide. Merz Aesthetics is part of Merz Group, a family-owned business founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com .
Copyright © 2022 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005051/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom